1Ryan WR, Allan RN, Yamamoto T, et al. Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004,187 : 219-225.
2Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn' s disease : an intervention study. Gstroenterology, 2001,120:1093-1099.
3Gassull MA, Fernandez- Banares F, Cabre E, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn' s disease: results of a double blind randomized multicentre trial.Gut,2002,51 : 164-168.
4Lochs H, Mayer M, Fleig WE, et al. prophylaxis of postoperative relapse in Crohn's disease with mesalamine : European cooperative Crohn's disease study Ⅵ. Gastroenterology, 2000,118 : 264-273.
5Mahmud N, Kamm MA, Dupas JL, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis:a double blind, parallel, randomised, multicentre study. Gut, 2001,49 :552-556.
6Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Advanced Drug Delivery Reviews,2005,57 :267-279
7Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules in active Crohn's disease: a randomized placebo- controlled study in the United States. Am J Gastroenterol,2002,97 : 1748-1754.
8Egan LJ, Sandbom WJ. Advances in the treatment of Crohn' s disease.Gastroenterology ,2004,126:1574-1581.
9Kusugami K, Ina K, Ando T, et al. Immunomodulatory therapy for inflammatory bowel disease. J Gastroenterol,2004,39:1129-1137.
10Rutgeerts P, Assche GV, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology,2004,126:1593-1610.
2Klotz U,Schwab M.Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.Advanced Drug Delivery Reviews,2005,57:267-279.
3Hanauer SB.Review article:high-dose aminosalicylatesto induce and maintain remissions in ulcerative colitis.Aliment Pharmacol Ther,2006,24(Suppl 3):37-40.
4Hanauer SB.Review article:high-dose aminosalicylatestoinduce and maintain remissions in ulcerative colitis[J].Aliment Pharmacol Ther,2006,24(Suppl 3):37-40.
7Saemann MD,Bohmig GA,Zlabinger GJ.Short-chain fattyacids:bacterial mediators of a balanced host microbial relation-ship in the human gut[J].Wien Klin Wochenschr,2002,114(829):289-300.
